Step Pharma

Step Pharma

Recherche en biotechnologie

Saint-Genis-Pouilly, Auvergne-Rhône-Alpes 1 699 abonnés

Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases

À propos

Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. Step Pharma’s lead program dencatistat (STP938) is a first in class, potent, selective, oral inhibitor of CTPS1 with demonstrated anti-tumor activity. Dencatistat entered clinical development in 2022 in a PhI/II study for the treatment of relapsed and refractory T-cell and B-cell lymphoma. More recently a solid tumour study was started focused on ovarian cancer using the concept of synthetic lethality and biomarker selection of patients. This can ultimately be viewed as a tumour agnostic approach with ovarian cancer being the PoC indication and future plans to expand into other tumour types such as NSCLC with high prevalence of the biomarker.

Secteur
Recherche en biotechnologie
Taille de l’entreprise
2-10 employés
Siège social
Saint-Genis-Pouilly, Auvergne-Rhône-Alpes
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2014

Lieux

Employés chez Step Pharma

Nouvelles

Pages similaires

Parcourir les offres d’emploi

Financement